Clinical and laboratory characteristics of 1179 Czech adolescents evaluated for antibodies to human adenovirus 36
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23732656
DOI
10.1038/ijo.2013.72
PII: ijo201372
Knihovny.cz E-resources
- MeSH
- Adenovirus E1B Proteins immunology metabolism MeSH
- Adiponectin blood MeSH
- Biomarkers blood MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Body Mass Index MeSH
- Insulin blood MeSH
- Blood Glucose metabolism MeSH
- Blood Pressure MeSH
- Cholesterol, LDL blood MeSH
- Humans MeSH
- Adenoviruses, Human immunology MeSH
- Adolescent MeSH
- Disease Susceptibility MeSH
- Pediatric Obesity epidemiology immunology virology MeSH
- Odds Ratio MeSH
- Peptide Fragments immunology metabolism MeSH
- Waist-Hip Ratio MeSH
- Antibodies, Viral blood MeSH
- Risk Factors MeSH
- Body Composition MeSH
- Triglycerides blood MeSH
- Check Tag
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Adenovirus E1B Proteins MeSH
- adenovirus E1B protein (368-381) MeSH Browser
- Adiponectin MeSH
- Biomarkers MeSH
- Insulin MeSH
- Blood Glucose MeSH
- Cholesterol, LDL MeSH
- Peptide Fragments MeSH
- Antibodies, Viral MeSH
- Triglycerides MeSH
BACKGROUND: Human adenovirus 36 (Adv36) is associated with obesity in children. Most prior studies have been small and the association of Adv36 status with markers of metabolic risks has been inconsistent. OBJECTIVES: To determine the prevalence of Adv36 antibodies in different weight categories of adolescents and to evaluate the association of Adv36 infection with anthropometric parameters and cardiometabolic health risks. SUBJECTS AND METHODS: In 1179 Czech adolescents (85 underweight, 506 normal weight, 160 overweight and 428 obese), the following variables were evaluated: anthropometric (body weight, height, body mass index, circumferences, fat mass), blood pressure, biochemical and hormonal (lipid profile, glucose, insulin, liver enzymes, adiponectin) and Adv36 antibodies (enzyme-linked immunosorbent assay). RESULTS: Of the total cohort, 26.5% were positive for Adv36 antibodies (underweight: 22.3%; normal weight: 21.5%; overweight: 40.0% and obese: 28.0%). The odds ratio for Adv36 antibody positivity evaluated vs normal weight was 2.61 for overweight (95% confidence interval (CI): 1.77-3.86, P<0.001) and 1.46 for obesity (95% CI: 1.07-1.99, P=0.016). A significantly higher prevalence of Adv36 infection was observed in female subjects (32.5%) in comparison to male subjects (19.7%; P<0.001). Adv36 positivity of the whole cohort was significantly related to body weight (P=0.042), body mass index (P=0.015), hip circumference (P=0.004), body height z-score (P=0.029), and total body fat (P=0.000) and trunk fat (P=0.000). Adv36 antibody-positive girls demonstrated significantly higher body height (167.8 vs 165.0 cm, P=0.01) and waist circumference (77.0 vs 72.0 cm, P=0.01). Infected adolescents exhibited significantly higher levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), but lower levels of blood glucose. Liver enzymes were significantly increased only in Adv36-positive boys. CONCLUSION: These results demonstrated an association of Adv36 antibodies with obesity and an even greater association with overweight. Adv36 positivity was related to increased fat mass, levels of TC and LDL-C, but to decreased level of blood glucose. No relation to adiponectin levels was revealed.
See more in PubMed
Diabetes. 2008 Sep;57(9):2321-31 PubMed
Obesity (Silver Spring). 2011 Jan;19(1):220-1 PubMed
Crit Rev Food Sci Nutr. 2009 Nov;49(10):868-913 PubMed
Cell Microbiol. 2013 Jan;15(1):53-62 PubMed
Int J Obes (Lond). 2005 Mar;29(3):281-6 PubMed
Stem Cells. 2008 Apr;26(4):969-78 PubMed
Int J Obes (Lond). 2009 Dec;33(12):1402-9 PubMed
Pediatrics. 2010 Oct;126(4):721-6 PubMed
Int J Obes Relat Metab Disord. 2001 Jul;25(7):990-6 PubMed
Int J Obes (Lond). 2010 Feb;34(2):302-8 PubMed
Cas Lek Cesk. 2010;149(9):417-22 PubMed
PLoS One. 2012;7(7):e42031 PubMed
PLoS One. 2012;7(7):e41652 PubMed
Obesity (Silver Spring). 2011 Jan;19(1):2; author reply 3 PubMed
Dig Dis Sci. 2012 Feb;57(2):535-44 PubMed
Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 PubMed
World Health Organ Tech Rep Ser. 1995;854:1-452 PubMed
Liver Int. 2010 Feb;30(2):184-90 PubMed
Obesity (Silver Spring). 2011 May;19(5):1083-9 PubMed
Microbiol Immunol. 1992;36(1):99-103 PubMed
Cent Eur J Public Health. 2004 Sep;12(3):126-30 PubMed
Int J Obes (Lond). 2010 Jan;34(1):89-93 PubMed
Endocr Relat Cancer. 2011 Apr 02;18(3):311-21 PubMed
Int J Obes (Lond). 2012 Feb;36(2):281-5 PubMed
J Nutr. 2001 Oct;131(10):2794S-2797S PubMed
World J Pediatr. 2011 Feb;7(1):16-23 PubMed
Int J Pediatr Obes. 2010 Apr;5(2):157-60 PubMed
Nat Rev Genet. 2012 Feb 07;13(3):175-88 PubMed
Obes Rev. 2004 May;5 Suppl 1:4-104 PubMed